ACR Poster Session A Systemic Lupus Erythematosus - Animal Models 422. Altered microRNA Expression in the Murine Tri-Congenic B6.Sle123 Model. Barry Garchow 1 , Yiu Tak Leung 3 , Roberto Caricchio 2 and Marianthi Kiriakidou 1 , 1 Department <strong>of</strong> Medicine, University <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Philadelphia, PA, 2 Temple Univ Med Office Bldg, Philadelphia, PA, 3 Thomas Jefferson University Hospital, Philadelphia, PA. 423. Amelioration <strong>of</strong> Lupus Nephritis by a Macromolecular Prodrug <strong>of</strong> Dexamethasone in NZB/W F1 Mice. Fang Yuan 2 , Richard K. Nelson 2 , Xin-ming Liu 2 , Karen A. Gould 2 and Dong Wang 1 , 1 Univ Nebraska Med Ctr, Omaha, NE, 2 University <strong>of</strong> Nebraska Medical Center. 424. An Intrinsic B Cell Defect That Affects Toll-Like Receptor Signaling Supports Autoimmunity in New Zealand Black Chromosome 13 Congenic Mice. Christina Loh 2 , Evelyn Pau 3 , Nan-Hua Chang 1 and Joan E. Wither 2 , 1 University Health Network, 2 University <strong>of</strong> Toronto, Toronto, ON, Canada, 3 University <strong>of</strong> Toronto. 425. Breach <strong>of</strong> B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice. Nan-Hua Chang 1 , Evelyn Pau 3 , Christina Loh 3 and Joan E. Wither 2 , 1 Toronto Western Research Institute, Toronto, ON, Canada, 2 University Health Network, Toronto, ON, Canada, 3 University <strong>of</strong> Toronto. 426. Dysfunction <strong>of</strong> Hematopoietic Stem Cells in Lupus Mice. Haitao Niu 2 , Luokun Xie 3 , Laurence Marguerite Morel 4 , Betty Diamond 1 and Yong-rui Zou 3 , 1 Feinstein Institute for Medical Research, Manhasset, NY, 2 The Feinstein Institute for Medical Research, Manhasset, NY, 3 The Feinstein Institute for Medical Research, 4 University <strong>of</strong> Florida. 427. Engraftment <strong>of</strong> PBMC from SLEand ACL Donors into BALB- Rag2 -/- IL2Rgc - KO Mice: A Promising Model for Studying SLE. Danieli Andrade 1 , Milena Vukelic 2 , Patricia B. Redecha 1 , Xiaoping Qing 1 , Giorgio Perino 3 , Jane E. Salmon 2 and Gloria C. Koo 4 , 1 Hospital for Special Surgery, NY, NY, 2 Hospital for Special Surgery, New York, NY, 3 Hospital for Special Surgery, NY, NY, 4 Hospital for Special Surgery, New York, NY. 428. Enhancement <strong>of</strong> IL-17 and Interferon-gamma Inflammatory Pathways in IRF9-/- MRL/lpr Mice with Disrupted Type I Interferon Signaling. Alvina D. Chu 2 , Nicole H. Kattah 3 , Michael T. Wong 3 , Catherine Tadina 3 and Paul J. Utz 1 , 1 Stanford Univ Schl <strong>of</strong> Med, Stanford, CA, 2 Stanford University School <strong>of</strong> Medicine, Palo Alto, CA, 3 Stanford University School <strong>of</strong> Medicine. 429. Epistatic Interactions between Lupus Susceptibility Loci on New Zealand Black Chromosomes 1 and 13 Lead to Marked Expansion <strong>of</strong> Dendritic Cell Populations but Have Little Effect on Autoimmunity. Yui Ho Cheung 2 , Evelyn Pau 2 and Joan E. Wither 1 , 1 University Health Network, Toronto, ON, Canada, 2 University <strong>of</strong> Toronto, Toronto, ON, Canada. 430. Hypercholesterolaemia and Autoimmunity Interact in a Mouse Model <strong>of</strong> Systemic Lupus Erythematosus To Enhance Both Atherosclerosis and Renal Inflammation, but by Distinct Mechanisms. Myles J. Lewis 2 , Talat H. Malik 2 , Liliane M. Fossati- Jimack 2 , Daniele Carassiti 2 , Terence H. Cook 2 , Dorian O. Haskard 1 and Marina Botto 1 , 1 Imperial <strong>College</strong>, London, United Kingdom, 2 Imperial <strong>College</strong>. 431. IL-17 Promotes Autoimmunity in Pristane-Induced Lupus. Elaine V. Lourenco, Chunlin Cai, Bevra H. Hahn and Antonio La Cava, UCLA. 432. IL-21 Promotes Autoimmune Features in Chronic Graft Versus Host Disease by Enhancing T Follicular Helper Development and B Cell Response. Vinh Nguyen 3 , Irina G. Luzina 1 , Qing Chen 1 , Horea Rus 1 and Violeta Rus 2 , 1 Baltimore, MD, 2 Univ <strong>of</strong> Maryland Schl <strong>of</strong> Med, Baltimore, MD, 3 University <strong>of</strong> Maryland School <strong>of</strong> Medicine, Baltimore, MD. 433. Interferon Regulatory Factor-5 (IRF-5) Is Critical for the Development <strong>of</strong> Lupus in MRL/lpr Mice. Yoshifumi Tada 3 , Seiji Kondo 4 , Shigehisa Aoki 2 , Syuichi Koarada 3 , Hisako Inoue 3 , Rie Suematsu 3 , Akihide Ohta 1 and Kohei Nagasawa 3 , 1 Department <strong>of</strong> Clinical Nursing, Saga University, Saga, Japan, 2 Department <strong>of</strong> Pathology, Saga University, Saga, Japan, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Saga University, Saga, Japan, 4 National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. 434. Interferonα Causes SLE by Expanding CD3+ CD4- CD8- Double Negative T Cell (DN T Cell). Chieri Akiyama 1 , Eriko Honda 1 , Akira Hashiramoto 2 , Dean W. Felsher 3 and Shunichi Shiozawa 2 , 1 Department <strong>of</strong> Biophysics, Graduate School <strong>of</strong> Health Science, Kobe University, Kobe, Hyogo, Japan, 2 Department <strong>of</strong> Biophysics, Graduate School <strong>of</strong> Health Science, Kobe University/ Department <strong>of</strong> Medicine, Graduate School <strong>of</strong> Medicine, Kobe University/The Center for Rheumatic Disease, Kobe University Hospital, Kobe, Japan, 3 Stanford University, School <strong>of</strong> Medicine, Division <strong>of</strong> Oncology, Department <strong>of</strong> Medicine and Pathology, Stanford, CA. 435. IRF4-Deficient Lupus-Prone MRL/lpr Mice Lack Serum Ig/ Auto-Abs and Th17 Cells but Develop Non-Immune Complex- Mediated Diffuse Proliferative Glomerulonephritis and Dermatitis/Ear Necrosis. Hideharu Sekine 4 , Takeshi Machida 1 , Eiji Suzuki 3 , Efrain Martinez Avila 3 , Phil Ruiz 5 , Christopher M. Reilly 6 and Gary S. Gilkeson 2 , 1 Fukushima Medical University, Fukushima, Japan, 2 Med Univ <strong>of</strong> South Carolina, Charleston, SC, 3 Medical University <strong>of</strong> South Carolina, Charleston, SC, 4 Medical University <strong>of</strong> South Carolina/Fukushima Medical University, Charleston, SC, 5 University <strong>of</strong> Miami, Miami, FL, 6 Virginia Tech, VA. 436. Long-Term Anti-CD20 Treatment Reduces Antibody-Secreting Ells in NZB/W Lupus Mouse. Wensheng Wang 2 , Terasa Owen 2 , Travis Ichikawa 2 and Jennifer H. Anolik 1 , 1 University <strong>of</strong> Rochester, Rochester, NY, 2 University <strong>of</strong> Rochester Medical Center, Rochester, NY. 437. Mitochondrial Dysfunction in T Cells Precede Disease Development in Lupus-Prone Mice. Tiffany Telarico 4 , David R. Fernandez 4 , Ann F. H<strong>of</strong>bauer 2 , Gary S. Gilkeson 1 , Jim C. Oates 3 and Andras Perl 5 , 1 Med Univ <strong>of</strong> South Carolina, Charleston, SC, 2 Medical University <strong>of</strong> South Carolina, 3 MUSC, Charleston, SC, 4 SUNY, 5 Upstate Medical Univ, Syracuse, NY. 438. Molecular Mechanisms <strong>of</strong> Lupus Dyslipidemia in Mice. Nilamadhab Mishra 1 , Kailin Yan 3 and Qiang Cao 2 , 1 Wake Forest Univ Health Scienc, Winston-Salem, NC, 2 Wake Forest University Health Sciences, 3 Wake Forest University Unv Health Sciences. 439. Nuclear Modifications during Apoptosis Are Required To Maintain Tolerance to Nuclear Antigens. Neelakshi R. Jog 1 , Eline Luning-Prak 2 and Roberto Caricchio 1 , 1 Temple University, 2 University <strong>of</strong> Pennsylvania. 440. PARP-1 Deficiency Leads to More Severe Glomerulonephritis and Increased Mortality in an Inducible Mouse Model <strong>of</strong> SLE. Maximilian F. Koenig 1 , Serena M. Bagnasco 1 , Janelle Montagne 1 , Antony Rosen 2 and Thomas Grader-Beck 2 , 1 Johns Hopkins School <strong>of</strong> Medicine, 2 Johns Hopkins School <strong>of</strong> Medicine, Baltimore, MD. 176 2010 Program Book
ACR Poster Session A 441. Recombinant Chaperonin 10 Suppresses Cutaneous Lupus and Lupus Nephritis in MRL-(Fas)lpr Mice. Onkar P. Kulkarni 3 , Mi Ryu 3 , Claudia Kantner 3 , Miklos Sardy 2 , Dean Naylor 1 , Richard Brown 1 , Daina Vanags 1 and Hans-Joachim Anders 3 , 1 CBio Ltd, Eight Mile Plains, Queensland, Australia, 2 Department <strong>of</strong> Dermatology and Allergology, University <strong>of</strong> Munich, Munich, Germany, 3 Medizinische Poliklinik-Innenstadt, University <strong>of</strong> Munich, Munich, Germany. 442. TGF-β-Induced CD4+Foxp3+ Cells Suppress Lupus-Like Syndrome through Induction <strong>of</strong> Formation <strong>of</strong> Tolerogenic DC. Xiaohui Zhou 4 , Julie Wang 4 , David A. Horwitz 2 , Huimin Fan 3 , Hejian Zou 1 , Zhongmin Liu 3 and Song Guo Zheng 4 , 1 Fudan University Medical School, 2 LAC/USC Medical Center, Los Angeles, CA, 3 Tongji University Medical School, 4 University <strong>of</strong> Southern California. 443. Widespread Upregulation <strong>of</strong> mEPCR in Kidney, Spleen and Liver <strong>of</strong> a Nephritic NZM B/W F1: Implications to Microvascular Disease. Sherry Xu 1 and Robert M. Clancy 2 , 1 NYU School <strong>of</strong> Medicine, 2 Tisch Hospital 4 - 407 , New York, NY. Systemic Lupus Erythematosus - Clinical Aspects and Treatment I 444. Anti C1q Antibodies in Patients with Systemic Lupus Erythematosus and Cutaneous Vasculitis: A Controlled Study. Shirish R. Sangle 1 , Loh Yet Lin 2 , Esther Sanchez 2 , Davies Rachel 2 and David P. D’Cruz 2 , 1 St Thomas’ Hospital, London, United Kingdom, 2 St Thomas’ Hospital, United Kingdom. 445. Antimalarials May Attenuate the Risk <strong>of</strong> Metabolic Syndrome in SLE: Results from an International Imception Cohort Registry. M. H. X. Ting 2 , R. P. Donn 3 , M. Lunt 3 , M. B. Urowitz 4 , D. D. Gladman 1 , D. Ibanez 1 , C. Gordon 1 , S. C. Bae 1 , A. Clarke 1 , S. Bernatsky 1 , J. Hanly 1 , D. Isenberg 1 , A. Rahman 1 , J. Sanchez- Guerrero 1 , J. Romero-Diaz 1 , P. R. Fortin 1 , D. Wallace 1 , E. Ginzler 1 , A. Vasudevan 1 , J. Merrill 1 , G. S. Alarcon 1 , B. Fessler 1 , G. Sturfelt 1 , O. Nived 1 , K. Steinsson 1 , M. Khamashta 1 , M. Petri 1 , S. Manzi 1 , M. Dooley 1 , R. Ramsey-Goldman 1 , C. Aranow 1 , R. Van Vollenhoven 1 , M. Ramos 1 , T. Stoll 1 , K. Kalunian 1 , A. Zoma 1 , P. Maddison 1 and I. N. Bruce 3 , 1 Systemic Lupus International Collaborating Clinics, Toronto, ON, Canada, 2 The University <strong>of</strong> Manchester, Salford, Manchester, United Kingdom, 3 The University <strong>of</strong> Manchester, 4 Toronto Western Hospital, Toronto, ON, Canada. 446. Arthritis in an Ethnically Diverse Systemic Lupus Erythematosus Population. Guada Respicio 1 , Clare Cleveland 1 , Kim Taylor 1 and Lindsey A. Criswell 2 , 1 Rosalind Russell Medical Research Center for Arthritis, University <strong>of</strong> California, San Francisco, San Francisco, CA, 2 UCSF-Box 0500, San Francisco, CA. 447. Association <strong>of</strong> Low-Dose Pulsed Intravenous Cyclophosphamide Therapy and Amenorrhea in 62 Patients with Systemic Lupus Erythematosus: A Case-Control Study. Sayumi Baba 1 , Yasuhiro Katsumata 4 , Yasushi Kawaguchi 2 , Kae Takagi 1 , Takahisa Gono 1 , Yuko Okamoto 1 , Yuko Ota 1 , Masako Hara 1 and Hisashi Yamanaka 3 , 1 Tokyo Women’s Medical University, Tokyo, Japan, 2 Tokyo Women’s Medical University, Tokyo, Japan, 3 Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan, 4 Tokyo Women’s Medical University. 448. Atherosclerotic Vascular Events in a Multinational Inception Cohort <strong>of</strong> SLE: Description and Attribution over an 8 Year Period. Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique Ibanez 32 , Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E. Clarke 15 , Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 , John G. Hanly 19 , David A. Isenberg 24 , Anisur Rahman 25 , Paul R. Fortin 33 , Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 , Graciela S. Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar K. Sturfelt 27 , Ola Nived 27 , Kristjan Steinsson 12 , Munther A. Khamashta 21 , Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi 34 , Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 , Cynthia B. Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 , Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 , Diane L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 30 , 1 West Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta, GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital, East Kilbride, United Kingdom, 6 Hanyang University Medical Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital Clinico I Provincial, Spain, 8 Hospital de Cruces, Universidad del Pais Vasco, Spain, 9 Instituto Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantonsspital Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University Hospital, Sweden, 12 Landspitalinn University Hospital, Iceland, 13 Manchester Royal Infirmary, Manchester, United Kingdom, 14 Medical University <strong>of</strong> South Carolina, Charleston, SC, 15 Montreal General Hospital, Montreal, QC, Canada, 16 North West Whales NHS Trust, Colwyn Bay, United Kingdom, 17 Northwestern University, Chicago, IL, 18 Oklahoma Med Research Foundation, Oklahoma City, OK, 19 Queen Elizabeth II Health Services Center, Halifax, NS, Canada, 20 SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne Institute, London, United Kingdom, 22 Toronto Western Hospital, Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL, 24 UCL Div <strong>of</strong> Medicine, London, United Kingdom, 25 UCL Div <strong>of</strong> Medicine, United Kingdom, 26 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 27 University Hospital Lund, Lund, Sweden, 28 University <strong>of</strong> Alabama, Oakland, CA, 29 University <strong>of</strong> Birmingham, Birmingham, United Kingdom, 30 University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 31 University <strong>of</strong> North Carolina, Chapel Hill, NC, 32 University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital, 33 University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada, 34 West Penn Allegheny Health System, Pittsburgh, PA. 449. Attention Deficit and Hyperactivity Disorder Scores Are Elevated and Associated with Disease Activity and Fatigue in Patients with Systemic Lupus Erythematosus. Ricardo J. Garcia, Lisa Francis, Maha Dawood, Irene Ramos, Stephen Faraone and Andras Perl, SUNY. 450. Autoantibody Response to Adjuvant and Non-Adjuvant H1N1 Vaccination in SLE. Murray B. Urowitz, Anoja Anton, Domonique Ibañez and Dafna D. Gladman, Toronto Western Hospital, Toronto, ON, Canada, Toronto Western Hospital, Toronto, ON, Canada. 451. Belimumab, a BLyS-Specific Inhibitor, Reduced Corticosteroid Use in Patients with Active SLE: Results from the Phase 3 BLISS-52 and -76 Studies. R. F. van Vollenhoven 9 , A. Gallacher 3 , S. Navarra 11 , E. M. Ginzler 8 , M. A. Dooley 10 , R. Cervera 4 , E. K. Li 2 , R. A. Levy 5 , R. Gúzman 7 , Z. J. Zhong 6 , S. Cooper 6 , L. Pineda 6 , D. Hough 6 , D. J. Wallace 1 and for the BLISS- 52 and - 76 Study Groups, 1 Cedars-Sinai/UCLA, Los Angeles, CA, 2 Chinese University <strong>of</strong> Hong Kong, Hong Kong, China, 3 Hospital Británico de Buenos Aires, Argentina, 4 Hospital Clinic, Barcelona, Spain, 5 Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, 6 Human Genome Sciences, Inc, Rockville, MD, 7 SaludCoop, Bogotá, Colombia, 8 SUNY Downstate Medical Center, Brooklyn, NY, 9 The Karolinska Institute, Stockholm, Sweden, 10 University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC, 11 University <strong>of</strong> Santo Tomas Hospital, Manila, Philippines. 2010 Program Book 177
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128: Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130: 5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132: 4:30 PM 2198. Association between V
- Page 133 and 134: ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136: THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138: • apply these basic statistics to
- Page 139 and 140: 9:15 AM The ACR/EULAR Definition of
- Page 141 and 142: Immunology, Oslo University Hospita
- Page 143 and 144: 9:15 AM 2239. Factors Associated wi
- Page 145 and 146: Upon completion of this session, pa
- Page 147 and 148: Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150: Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152: ACR Poster Session A Cytokines, Med
- Page 153 and 154: ACR Poster Session A 51. Associatio
- Page 155 and 156: ACR Poster Session A 83. Respirator
- Page 157 and 158: ACR Poster Session A 121. Bone Dens
- Page 159 and 160: ACR Poster Session A 142. The Intra
- Page 161 and 162: ACR Poster Session A 171. Early Pro
- Page 163 and 164: ACR Poster Session A Pediatric Rheu
- Page 165 and 166: ACR Poster Session A 233. Prevalenc
- Page 167 and 168: ACR Poster Session A 266. Subtype S
- Page 169 and 170: ACR Poster Session A 297. Body Weig
- Page 171 and 172: ACR Poster Session A 325. Patient R
- Page 173 and 174: ACR Poster Session A 356. Influence
- Page 175 and 176: ACR Poster Session A 383. Efficacy
- Page 177: ACR Poster Session A 409. Rituximab
- Page 181 and 182: ACR Poster Session A 465. Immunoglo
- Page 183 and 184: ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186: ACR Poster Session A 521. DC-STAMP
- Page 187 and 188: ACR Poster Session A 546. Prevalenc
- Page 189 and 190: ACR Poster Session A 571. Epidemiol
- Page 191 and 192: ACR Poster Session A 599. Validatio
- Page 193 and 194: ACR/ARHP Poster Session B Halls B1
- Page 195 and 196: ACR Poster Session B 767. Economic
- Page 197 and 198: ACR/ARHP Poster Session B 792. The
- Page 199 and 200: ACR/ARHP Poster Session B Universit
- Page 201 and 202: ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204: ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206: ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208: ACR/ARHP Poster Session B 935. The
- Page 209 and 210: ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212: ACR Poster Session B 993. Early Exp
- Page 213 and 214: ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216: ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218: ACR Poster Session B 1084. Gene Exp
- Page 219 and 220: ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222: ACR Poster Session B hiroshima Memo
- Page 223 and 224: ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226: ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228: ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360:
A α-galactosylceramide 505 A2A kno
- Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
- Page 363 and 364:
cost-utility 759, 1539 couples 1324
- Page 365 and 366:
fibroblast like synoviocyte 27 fibr
- Page 367 and 368:
impact 1063, 1325 inactive disease
- Page 369 and 370:
methylation 826, 1253, 1489 methylt
- Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378:
Abelson, Abby Goulder, MD Education
- Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382:
ACR Annual Meeting fellowS-in-train
- Page 383 and 384:
NOTES 2010 Program Book 381
- Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
- Page 387 and 388:
Prescription Enbrel ® (etanercept)